Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

Cancer Research
Marion E Meijer-van GelderJohn A Foekens

Abstract

The prognostic value of components of the urokinase-type plasminogen activator (uPA) system, its receptor uPAR (CD87), and plasminogen activator inhibitors PAI-1 and PAI-2 is well established. We studied the predictive value of these proteolytic factors by evaluating the association of their tumor expression level and the efficacy of tamoxifen therapy in patients with recurrent breast cancer. The antigen levels of the four factors were determined by ELISA in cytosols prepared from estrogen receptor-positive primary breast tumors of 691 hormone-naive breast cancer patients with recurrent disease and treated with tamoxifen as first-line systemic therapy. High tumor levels of uPA (P < 0.001), uPAR (P < 0.01), and PAI-1 (P = 0.01) were associated with a lower efficacy of tamoxifen therapy. In the multivariable analysis, uPA (P < 0.001) provided additional information independent of the traditional predictive factors to predict benefit from tamoxifen therapy. High levels of uPA, uPAR, and PAI-1 predicted a shorter progression-free survival (PFS) on tamoxifen in an analysis of the first 9 months of therapy. However in the analysis during the total follow-up period, high PAI-2 levels (P = 0.01) showed a longer response to tamoxifen. I...Continue Reading

References

Jan 2, 1990·Molecular and Cellular Endocrinology·P A AndreasenS N Stacey
Nov 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A FoekensJ G Klijn
Oct 16, 1996·Journal of the National Cancer Institute·D F HayesR J Winn
Jul 3, 1997·International Journal of Cancer. Journal International Du Cancer·P A AndreasenM J Duffy
Jan 1, 1997·British Journal of Cancer·C DugganM J Duffy
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J F RobertsonR W Blamey
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Mar 5, 1999·Breast Cancer Research and Treatment·S G HilsenbeckG M Clark
Jul 2, 1999·Journal of Surgical Oncology·M J DuffyN O'Higgins
Sep 3, 1999·Breast Cancer Research and Treatment·A M SieuwertsJ A Foekens
Mar 22, 2002·The Lancet Oncology·V C Jordan
Jun 29, 2002·Breast Cancer Research and Treatment·A BuzdarUNKNOWN Droloxifene 301 Study Group
Oct 2, 2002·Breast Cancer Research and Treatment·Robert W Carlson

❮ Previous
Next ❯

Citations

Jun 13, 2008·Nature Reviews. Cancer·David R CroucherMarie Ranson
Oct 15, 2005·Current Opinion in Oncology·Julie DecockTanja Cufer
Mar 1, 2007·PloS One·Margarita GutovaKaren S Aboody
Jul 28, 2011·Breast Cancer : Basic and Clinical Research·Katherine Rak TkaczukGinette Serrero
Feb 27, 2008·Breast Cancer Research and Treatment·Danielle MeijerEls M J J Berns
Feb 13, 2013·Cancer Research·Aaron M LeBeauCharles S Craik
Mar 1, 2006·Expert Opinion on Biological Therapy·Tamara T LahCornelis J F Van Noorden
Mar 27, 2013·Chinese Medical Sciences Journal = Chung-kuo I Hsüeh K'o Hsüeh Tsa Chih·Ye JinBao-cai Xing
Oct 13, 2009·European Journal of Pharmacology·Supachai YodkeereePornngarm Limtrakul
Sep 23, 2008·Biochimica Et Biophysica Acta·Marinella ZilliUNKNOWN Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)
Apr 6, 2011·Journal of Cellular Physiology·Wen-Hsiu HsuWu-Hsien Kuo
Feb 20, 2014·Medicinal Research Reviews·Ahmed H MekkawyDavid L Morris
May 15, 2015·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Jasmine M Miller-KleinhenzLily Yang
Sep 12, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Amalia MilanoFatima Cardoso
Jul 5, 2005·Thrombosis Research·Mary Jo Mulligan-KehoeLeo R Zacharski
Aug 19, 2015·Frontiers in Pharmacology·Steven L Gonias, Jingjing Hu
Dec 1, 2014·Journal of Cancer Research and Clinical Oncology·Chafika MazouniPierre-Marie Martin
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurice P H M JansenEls M J J Berns
Sep 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Dec 13, 2006·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·A SalviG De Petro
Sep 6, 2011·Molecular and Cellular Biochemistry·Eun Ji KimJung Han Yoon Park
Jan 8, 2005·Clinical Chemistry·Michael J Duffy
Jan 20, 2018·Molecular Cancer Research : MCR·Thu H TruongJulie H Ostrander
Nov 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Sofie SchrohlJohn A Foekens
Oct 17, 2006·Molecular Cancer Therapeutics·Ralph J Abi-HabibArthur E Frankel
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anieta M SieuwertsJohn A Foekens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.